LivaNova PLC LIVN
Regular-session close
After hours · Nov 20, 4:26 PM ET
- YTD
- +47.46%
- 1 year
- +69.84%
5D +0.21 (+0.23%)
- Market cap
- 5.00B
- Revenue (ttm)
- 1.51B
- Profit margin
- 13.01%
- EPS (ttm)
- 3.49
- Shares out
- 55.09M
- P/E ratio
- 26.00
- Forward P/E
- 19.18
- YTD return
- +47.46%
- 1-year return
- +69.84%
- 50-day average
- 81.35
- Volume
- 499.88K
- Avg volume
- 688.45K
- Open
- 91.61
- Previous close
- 92.07
- Day's range
- 90.15 – 93.16
- 52-week range
- 53.48 – 99.38
- Beta
- 0.92
- Analysts
- Buy
- Price target
- 105.09 (+15.8%)
- Earnings date
- Feb 24, 2027
Key statistics
- 200-day average
- 74.72
- Enterprise value
- 4.87B
- PEG ratio
- 0.93
- Price / sales
- 3.32
- Price / book
- 3.64
- Revenue growth
- 9.90%
- Free cash flow
- 67.71M
- Total cash
- 563.47M
- Total debt
- 357.07M
- Return on equity
- 15.50%
- Short % of float
- 13.26%
Fundamental scorecard
12 of 25 checks passed on LIVN’s reported financials
12of 25 checks passed
- Value 0 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 75.00
- Target (mean)
- 105.09
- Target (high)
- 120.00
- Strong buy3
- Buy6
- Hold1
- Sell0
- Strong sell1
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.9707.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.98 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 1.06 | 1.23 | +0.17 | +16.04% |
| Aug 5, 2026 | Jun 30, 2026 | 1.09 | 1.26 | +0.17 | +15.60% |
| May 6, 2026 | Mar 31, 2026 | 0.85 | 0.98 | +0.13 | +15.29% |
| Feb 25, 2026 | Dec 31, 2025 | 0.80 | 0.86 | +0.06 | +7.50% |
| Nov 5, 2025 | Sep 30, 2025 | 0.919 | 1.11 | +0.19 | +20.78% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Barclays | main | Overweight | Overweight |
| Nov 5, 2026 | Baird | main | Outperform | Outperform |
| Nov 4, 2026 | Needham | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Sep 2, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Aug 5, 2026 | Needham | main | Buy | Buy |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United Kingdom
- Website
- livanova.com
News
Freedom Capital Markets Maintains Hold on LivaNova, Raises Price Target to $89
Barclays Maintains Overweight on LivaNova, Raises Price Target to $120
Baird Maintains Outperform on LivaNova, Raises Price Target to $111
Needham Maintains Buy on LivaNova, Raises Price Target to $112
12 Health Care Stocks Moving In Wednesday's Intraday Session
Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday LivaNova Raises FY2026 Adj EPS Guidance from $4.30-$4.40 to $4.40-$4.50 vs $4.37 Est; Raises FY2026 Sales Guidance from $1.499B-$1.513B to $1.513B-$1.527B vs $1.522B Est
LivaNova Q3 Adj. EPS $1.23 Beats $1.06 Estimate, Sales $393.100M Beat $381.067M Estimate
LivaNova Publishes Results In Neuromodulation: Technology At The Neural Interface Regarding Its CORE-VNS Trial Of Its VNS Therapy Devices
Your note
Sign in to keep a note on LIVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRY JAMES CHRISTOPHER | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 7,918 |
| BOLTON STEPHANIE | Officer | Conversion of Exercise of derivative security | Mar 29, 2026 | 22,189 |
| ENXING SENG STACY | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 15,307 |
| KOZY WILLIAM A | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 37,566 |
| MAKATSARIA VLADIMIR A. | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 29, 2026 | 14,167 |
| O'KANE SHARON | Director | Conversion of Exercise of derivative security | Jun 12, 2025 | 11,304 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.05% | 7,739,664 | 702.22M | Sep 29, 2026 |
| Primecap Management Company | 7.60% | 4,187,158 | 379.90M | Sep 29, 2026 |
| FMR, LLC | 7.22% | 3,976,650 | 360.80M | Sep 29, 2026 |
| Invesco Ltd. | 5.29% | 2,914,016 | 264.39M | Sep 29, 2026 |
| Hood River Capital Management LLC | 4.66% | 2,568,241 | 233.02M | Sep 29, 2026 |
| State Street Corporation | 3.93% | 2,166,157 | 196.54M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,963,642 | 178.16M | Sep 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 3.45% | 1,902,700 | 172.63M | Jun 29, 2026 |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 3.05% | 1,679,556 | 152.39M | Jul 30, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.92% | 1,607,363 | 145.84M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.63% | 1,450,682 | 131.62M | Sep 29, 2026 |
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 2.50% | 1,374,576 | 124.72M | Jun 29, 2026 |
